One of the central regulators of cellular and organismal metabolism in eukaryotes is AMP-activated protein kinase (AMPK), which is activated when intracellular ATP production decreases. AMPK has critical roles in regulating growth and reprogramming metabolism, and has recently been connected to cellular processes such as autophagy and cell polarity. Here we review a number of recent breakthroughs in the mechanistic understanding of AMPK function, focusing on a number of newly identified downstream effectors of AMPK.
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One of the fundamental requirements of all cells is to balance ATP consumption and generation. AMPK is a highly conserved sensor of intracellular adenosine nucleotide levels that is activated when even modest decreases in ATP production result in relative increases in AMP or ADP. AMPK promotes catabolic pathways to generate more ATP, and inhibits anabolic pathways. Genetic analysis of AMPK orthologues in Arabidopsis 1 , Saccharomyces cerevisiae 2 , Dictyostelium 3 , Caenorhabditis elegans 4 , Drosophila 5 and even the moss Physcomitrella patens 6 has revealed a conserved function of AMPK as a metabolic sensor that allows for adaptive changes in growth, differentiation and metabolism under conditions of low energy. In eukaryotes like mammals, AMPK has a general role in coordinating growth and metabolism, and specialized roles in metabolic control in dedicated tissues, such as the liver, muscle and fat 7 . In most species, AMPK exists as an obligate heterotrimer, containing a catalytic subunit (α), and two regulatory subunits (β and γ). AMPK is hypothesized to be activated by a two-pronged mechanism (for a full review, see ref. 8) . Under lowered intracellular ATP levels, AMP or ADP can directly bind to the γ regulatory subunits of AMPK, leading to a conformational change that promotes AMPK phosphorylation and also protects AMPK from dephosphorylation to ensure it remains activated. Recent studies showing that ADP can bind to the nucleotide-binding pockets in the γ subunit suggest it may be the physiological nucleotide for AMPK activation under a variety of cellular stresses 9, 10 . Phosphorylation of Thr 172 in the activation loop of AMPK is required for AMPK activation, and several groups have demonstrated that the serine/threonine kinase LKB1 directly mediates this event [11] [12] [13] . Interestingly, LKB1 (also known as STK11) is a tumour-suppressor gene that is mutated in the inherited cancer disorder Peutz-Jeghers syndrome and in a significant fraction of lung and cervical cancers, suggesting that AMPK could play a role in tumour suppression 14 . Importantly, AMPK can also be phosphorylated on Thr 172 in response to calcium flux, independently of LKB1, through CAMKK2 (also known as CAMKKβ) kinase, which is the closest mammalian kinase to LKB1 by sequence homology [15] [16] [17] [18] . Additional studies have suggested the MAPKKK (mitogen-activated protein kinase kinase kinase) family member TAK1 (also known as MAP3K7) may also phosphorylate Thr 172, but the contexts in which TAK1 might regulate AMPK in vivo, and whether that involves LKB1 still requires further investigation 19, 20 . In mammals, there are two genes encoding the AMPK α catalytic subunit (α1 and α2), two β genes (β1 and β2) and three γ subunit genes (γ1, γ2 and γ3) 7 . The expression of some of these isoforms is tissue-restricted, and functional distinctions are reported for the two catalytic α subunits, particularly the AMP-and LKB1-responsiveness and nuclear localization of AMPKα2, compared with AMPKα1 (ref. 21 ). However, the α1 subunit has been shown to localize to the nucleus under some conditions 22 . Additionally, the myristoylation of the β isoforms has been shown to be required for proper activation of AMPK and its localization to membranes 23 . Further control through regulation of AMPK [24] [25] [26] or LKB1 localization 27, 28 remains a critical underexplored area for future research. Tissue-specific deletion of LKB1 has revealed that it mediates the majority of AMPK activation in nearly every tissue type examined to date, although CAMKK2 seems to be particularly involved in AMPK activation in neurons and T cells 29, 30 . In addition to regulating AMPKα1 and AMPKα2 phosphorylation, LKB1 phosphorylates and activates another twelve kinases related to AMPK 31 . This family of kinases includes the MARKs (microtubuleaffinity regulating kinases; 1-4), SIKs (salt-inducible kinases; 1-3), BRSKs (brain-specific kinases, also known as SADs; 1 and 2) and NUAKs (1 and 2) 32 . Although only AMPKα1 and AMPKα2 are activated in response to energy stress, there is a significant amount of crosstalk and a number of shared substrates between AMPK and the AMPK-related kinases 14 . Many types of cellular stress can lead to AMPK activation. As well as physiological AMP/ADP elevation from stresses such as low nutrients or prolonged exercise, AMPK can be activated in response to several pharmacological agents (Fig. 1) . Metformin, the most widely prescribed Type 2 diabetes drug, has been shown to activate AMPK 33 , and does so in an LKB1-dependent manner 34 . Metformin and other biguanides, such as the more potent analogue phenformin 35 , are thought to activate AMPK by acting as mild inhibitors of Complex I of the respiratory chain, which leads to a drop of intracellular ATP levels 36, 37 . AICAR (5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside) is another AMPK agonist and is a cell-permeable precursor to ZMP (AICAR monophosphate), which mimics AMP, and binds to the AMPKγ subunits 38 . Interestingly, the chemotherapeutic pemetrexed, which is an inhibitor of thymidylate synthase, also inhibits AICART (aminoimidazolecarboxamide ribonucleotide formyltransferase), the second folate-dependent enzyme of purine biosynthesis, which results in increased intracellular ZMP and activation of AMPK, similar to AICAR treatment 39 . Finally, a number of naturally occurring compounds, including resveratrol, a polyphenol found in the skin of red grapes, have been shown to activate AMPK and yield similarly beneficial effects on metabolic disease as AICAR and metformin treatment 40, 41 . Resveratrol can rapidly activate AMPK through inhibition of the F1F0 mitochondrial ATPase 36 and the original studies suggesting that resveratrol directly binds and activates sirtuins have come into question 42, 43 . Indeed, the activation of the sirtuin SIRT1 by resveratrol in cells and mice seems to require increased NAD + levels by AMPK activity 44, 45 . The principle therapeutic mode of action of metformin in diabetes is through suppression of hepatic gluconeogenesis 46 , although it remains controversial whether AMPK is absolutely required for the glucose-lowering effects of metformin 47 . As metformin functions as a mitochondrial inhibitor, it should be expected to activate a variety of stress-sensing pathways that could redundantly serve to inhibit hepatic gluconeogenesis, of which currently AMPK is just one of the best appreciated. It will be critical to define the relative contribution of AMPK and other stress-sensing pathways affected by metformin in accurate in vivo models of metabolic dysfunction and insulin resistance in which these agents show therapeutic benefit. Nonetheless, metformin, AICAR 48 , the direct small-molecule AMPKactivator A769662 (ref. 49) , and genetic expression of activated AMPK in liver 50, 51 all lower blood-glucose levels and improve lipid profile 52 , leaving AMPK activation a primary goal for future diabetes therapeutics 53 . As a result of the diverse beneficial effects of this endogenous metabolic checkpoint in other pathological conditions, including several types of human cancer, there is an increasing interest in identifying novel AMPK agonists to be exploited for therapeutic benefits.
AMPK coordinates control of cell growth and autophagy
In conditions where nutrients are scarce, AMPK acts as a metabolic checkpoint inhibiting cellular growth. The most thoroughly described mechanism by which AMPK regulates cell growth is through suppression of the mTORC1 (mammalian target of rapamycin complex 1) pathway. One mechanism by which AMPK controls mTORC1 is by direct phosphorylation of the tumour suppressor TSC2 on Ser 1387 (Ser 1345 in rat TSC2). However, in eukaryotes that lack TSC2, and in Tsc2 -/-mouse embryonic fibroblasts (MEFs), AMPK activation still suppresses mTORC1 (refs 54,55) . This led to the discovery that AMPK also directly phosphorylates the mTORC1 subunit Raptor (regulatory associated protein of mTOR) on two conserved serines, which blocks the ability of the mTORC1 kinase complex to phosphorylate its substrates 42 .
As well as regulating cell growth, mTORC1 also controls autophagy, a cellular process of 'self engulfment' in which the cell breaks down its own organelles (macroautophagy) and cytosolic components (microautophagy) to ensure sufficient metabolites when nutrients run low. The most upstream components of the core conserved autophagy pathway include the serine/threonine kinase Atg1 and its associated regulatory subunits Atg13 and Atg17 (ref. 56) . In budding yeast, the Atg1 complex is inhibited by the TOR-Raptor complex (target of rapamycin complex 1; TORC1) [57] [58] [59] . The activity of the mammalian orthologues of the Atg1 complex are also suppressed by mTORC1 through a poorly defined mechanism that probably involves phosphorylation of the Atg1 homologues ULK1 and ULK2, as well as their regulatory subunits (reviewed in ref. 60) . In contrast to inhibitory phosphorylations from mTORC1, studies from a number of groups in the past year have revealed that the ULK1 complex is activated through direct phosphorylation by AMPK, which is critical for its function in autophagy and mitochondrial homeostasis (reviewed in ref. 61 ).
In addition to unbiased mass-spectrometry studies showing endogenous AMPK subunits are ULK1 interactors 62, 63 , two recent studies reported AMPK can directly phosphorylate several sites in ULK1 (refs 64,65) . Our lab found that hepatocytes and MEFs devoid of either AMPK or ULK1 had defective mitophagy and elevated levels of p62 (Sequestrosome-1), a protein involved in aggregate turnover, which is itself selectively degraded by autophagy 64 . As observed for other core autophagy proteins, ULK1 was required for cell survival following nutrient deprivation and this also requires phosphorylation of the AMPK sites in ULK1. Similarly, genetic studies in budding yeast 66 and in C. elegans 64 demonstrate that Atg1 is needed for the effect of AMPK on autophagy. Interestingly, Kim and colleagues found distinct sites in ULK1 targeted by AMPK, although they also found that AMPK regulation of ULK1 was needed for its function 65 . These authors also mapped a direct mTOR phosphorylation site in ULK1 that seems to dictate AMPK binding, a finding corroborated by another recent study, though the details differ 67 . Collectively, these studies show that AMPK can trigger autophagy in a double-pronged mechanism of directly activating ULK1 and inhibiting the suppressive effect of mTORC1 on ULK1 (Fig. 2) . Many of the temporal and spatial details of the regulation of these three evolutionarily ancient interlocking nutrient-sensitive kinases (AMPK, ULK1 and mTOR) remain to be decoded.
Interestingly, AMPK triggers the acute destruction of defective mitochondria through a ULK1-dependent stimulation of mitophagy, and stimulates de novo mitochondrial biogenesis through PGC-1α-dependent transcription (see below). Thus, AMPK controls mitochondrial homeostasis in a situation resembling a 'Cash for Clunkers' salvage mechanism, in which existing defective mitochondria are replaced by new fuel-efficient mitochondria (Fig. 3) . One context where AMPK control of mitochondrial homeostasis may be particularly critical is in the context of adult stem cell populations. In a recent study on haematopoetic stem cells, genetic deletion of LKB1 or genes encoding both AMPK catalytic subunits led to marked accumulation of defective mitochondria, as also found in fibroblasts that lack ULK1 or express ULK1 that does not contain AMPK-phosphorylation sites 68 .
Beyond effects on mTOR and ULK1, two other reported targets of AMPK in growth control are the tumour suppressor p53 (ref. 69 ) and the CDK (cyclin-dependent kinase) inhibitor p27 (refs 70,71) , although the reported sites of phosphorylation do not conform well to the AMPK substrate sequence found in other substrates. The recent discovery of AMPK family members controlling phosphatases 72 presents another The Ras/PI3K/mTOR pathways intersect the LKB1/AMPK pathway at multiple points. The gene encoding LKB1, the upstream kinase for AMPK, is the tumour-suppressor gene mutated in Peutz-Jeghers syndrome, as well a significant fraction of sporadic lung cancers and cervical cancers. PeutzJeghers syndrome patients share a number of clinical features with patients inheriting defective PTEN or TSC tumour suppressors, perhaps owing to the control of common biochemical pathways by these suppressors and LKB1, of which the mTORC1 pathway is currently the best understood. Extensive cross-regulation of the LKB1/AMPK pathway by the oncogenic Ras and PI3K pathways has been discovered, which may explain how these commonly mutated oncogenes circumvent this endogenous tumour suppressor pathway. The ULK1 kinase complex has emerged recently as a central node receiving inputs from both AMPK and mTORC1. A number of kinases that can phosphorylate specific residues in LKB1 or AMPK have been identified (upper inset), although the context in which most of these regulatory events occur is poorly defined at present, as is the functional impact of these phosphorylation events on AMPK signalling. The BHD tumour suppressor and its partner FNIP1, as well as the sestrin family of proteins, have also been implicated as being upstream or downstream of AMPK and mTOR depending on the context (bottom inset). Inhibitory phosphorylation events shown in yellow, activating phosphorylations shown in red.
mechanism by which AMPK might regulate protein phosphorylation, without being the kinase to directly phosphorylate the site.
Control of metabolism through transcription and direct effects on metabolic enzymes AMPK was originally defined as the upstream kinase for the critical metabolic enzymes acetyl-CoA carboxylase (ACC1 and ACC2) and HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase), which function in the rate-limiting steps for fatty-acid and sterol synthesis in a wide variety of eukaryotes 73, 74 . In specialized tissues such as muscle and fat, AMPK regulates glucose uptake through effects on the RabGAP (Rab GTPase-activating protein) TBC1D1, which along with its homologue TBC1D4 (also known as AS160), have key roles in GLUT4 trafficking following exercise and insulin 75 . In fat, AMPK also directly phosphorylates lipases, including hormone-sensitive lipase (HSL) 76 and adipocyte-triglyceride lipase (ATGL) 77 , with the latter an AMPK substrate also functionally conserved in C. elegans 4 . Interestingly, mammalian ATGL and its liberation of fatty acids has recently been shown to be important in rodent models of cancer-associated cachexia 78 . Whether AMPK is important in this context remains to be seen.
AMPK is also involved in adaptive metabolic reprogramming through transcriptional changes. Breakthroughs in this area have come through distinct lines of investigation. AMPK has been reported to phosphorylate and regulate a number of transcription factors and coactivators, the acetyltransferase p300, a subfamily of histone deacetylases, and even histones themselves. In 2010, Bungard et al., reported that AMPK can target transcriptional regulation through phosphorylation of histone H2B on Ser 36 (ref. 79 ). Cells expressing a mutant H2B
S36A blunted the induction of stress genes upregulated by AMPK including p21 and cpt1c 79, 80 . In addition, chromatin immunoprecipitation at the promoters of these genes detected AMPK at specific chromatin loci in mammalian cells, one of the first studies to do so 79 . Notably, Ser 36 in H2B does not conform well to the AMPK consensus 81 ; further studies will reveal whether this substrate is an exception or whether this phosphorylation is indirectly controlled.
AMPK activation has recently been linked to regulation of the circadian clock, which couples daily light and dark cycles to the control of physiology in a wide variety of tissues through tightly coordinated transcriptional programmes 82 . Several master transcription factors are involved in orchestrating this oscillating network. AMPK was shown to regulate the stability of the core clock component Cry1 though phosphorylation of Cry1 Ser 71, which stimulates the direct binding of the F-box protein Fbxl3 to Cry1, targeting it for ubiquitin-mediated degradation 22 . Importantly, this is the first example of AMPK-dependent phosphorylation inducing protein turnover, although this is a common mechanism used by other kinases. It is to be expected that additional substrates in which AMPK phosphorylation triggers degradation will be discovered. Another study linked AMPK to the circadian clock through effects on casein kinase 83 , although the precise mechanism requires further investigation. A recent genetic study in AMPK-deficient mice also indicates that AMPK modulates the circadian clock to different extents in different tissues 84 .
As the role of transcriptional programmes in the physiology of metabolic tissues is well studied, many connections between AMPK and transcriptional control have been found in these systems. Importantly, many of the transcriptional regulators phosphorylated by AMPK in metabolic tissues are expressed more ubiquitously than initially appreciated and may be playing more central roles tying metabolism to growth. One example that was recently discovered is the lipogenic transcriptional factor SREBP1 (ref. 85 ). SREBP1 induces a gene programme that includes the targets ACC1 and FASN, which stimulate fatty-acid synthesis in cells. In addition to being a critical modulator of lipids in liver and other metabolic tissues, SREBP1-mediated control of lipogenesis is needed in all dividing cells, as illustrated in a recent study identifying SREBP1 as a major cell-growth regulator in Drosophila and mammalian cells 86 . AMPK was recently found to phosphorylate a conserved serine near the cleavage site within SREBP1, suppressing its activation 85 . This further illustrates the acute and prolonged nature of the control of biology by AMPK. AMPK acutely controls lipid metabolism through phosphorylation of ACC1 and ACC2, while mediating long-term adaptive effects through phosphorylation of SREBP1 and loss of expression of lipogenic enzymes. AMPK has also been suggested to phosphorylate the glucosesensitive transcription factor ChREBP 87 , which dictates expression of an overlapping lipogenic gene signature with SREBP1 88 . Adding an extra complexity here is the observation that phosphorylation of the histone acetyltransferase p300 by AMPK and its related kinases affects the acetylation and activity of ChREBP (carbohydrate-response-element-binding protein) as well 89 . Interestingly, like SREBP1, ChREBP has also been shown to be broadly expressed and involved in growth control in some tumour cell settings, at least in cell culture 90 . Similarly, although best appreciated for roles in metabolic tissues, the CRTC (cyclic AMP-regulated transcriptional co-activators) family, which are transcriptional co-activators for CREB (cAMP response element binding protein) and its related family members, may also play roles in epithelial cells and cancer 91 . Recent studies in C. elegans revealed that phosphorylation of a CRTC orthologue by AMPK is needed for AMPK to promote lifespan extension 92 , reinforcing the potentially broad biological functions of these co-activators. In addition to these highly conserved targets of AMPK and its related kinases, AMPK has also been reported to phosphorylate the nuclear receptors HNF4α (also known as NR2A1) 93 and TR4 (also known as NR2C2) 94 , the co-activator PGC-1α 95 , and the zinc-finger protein AREBP (also known as ZNF692) 96 , although development of phospho-specific antibodies and additional functional studies are needed to further define the functional roles of these events.
Another recently described set of transcriptional regulators targeted by AMPK and its related family members across a range of eukaryotes are the class IIa family of histone deacetylases (HDACs) [97] [98] [99] [100] [101] [102] [103] . In mammals the class IIa HDACs comprise a family of four functionally overlapping members: HDAC4, HDAC5, HDAC7 and HDAC9 (ref. 104) . Similarly to CRTCs, class IIa HDACs are inhibited by phosphorylation by AMPK and its family members, resulting in 14-3-3 binding and cytoplasmic sequestration. Recently, we discovered that similar to CRTCs, in liver the class IIa HDACs are dephosphorylated in response to the fasting hormone glucagon, resulting in transcriptional increases that are normally opposed by AMPK. Once nuclear, class IIa HDACs bind FOXO-family transcription factors, stimulating their deacetylation and activation 102 , increasing expression of gluconeogenesis genes including genes encoding glucose-6-phosphatase and PEPCK (phosphoenolpyruvate carboxykinase). Collectively, these findings suggest AMPK suppresses glucose production through two transcriptional effects: reduced expression of CREB targets through CRTC inactivation, and reduced expression of FOXO-target genes through class IIa HDAC inactivation (Fig. 4) . It is worth noting that although AMPK activation inhibits expression of FOXO gluconeogenic targets in the liver, in other cell types AMPK is reported to stimulate a set of FOXO-dependent target genes in stress resistance through direct phosphorylation of novel sites in FOXO3 and FOXO4 (although not FOXO1) 105 , an effect which seems to be conserved in C. elegans 106 . Ultimately, defining the tissues, isoforms and conditions where the AMPK pathway controls FOXO through phosphorylation or acetylation is an important goal for understanding how these two evolutionarily ancient metabolic regulators are coordinated.
In addition to phosphorylating transcriptional regulators, AMPK has also been shown to regulate the activity of the deacetylase SIRT1 in some tissues through effects on NAD + levels 107, 108 . As SIRT1 targets a number of transcriptional regulators for deacetylation, this adds yet another layer of temporal-and tissue-specific control of metabolic transcription by AMPK. This has been studied best in the context of exercise and skeletal muscle physiology, where depletion of ATP activates AMPK and through SIRT1 promotes fatty acid oxidation and mitochondrial gene expression. Interestingly, AMPK was also implicated in skeletal muscle reprogramming in a study where sedentary mice were treated with AICAR for 4 weeks and were found to be able to perform 44% better than counterparts that received control vehicle 109 . This metabolic reprogramming was shown to require PPARβ/δ 109 and probably involves PGC-1α as well 95 , although the AMPK substrates critical in this process have not yet been rigorously defined. Interestingly, the only other single agent ever reported to have such endurance reprogramming properties besides AICAR is resveratrol 110 , whose action in regulating metabolism is now known to be critically dependent on AMPK 45 .
Control of cell polarity, migration and cytoskeletal dynamics
In addition to the ample data for AMPK in cell growth and metabolism, recent studies suggest that AMPK may control cell polarity and cytoskeletal dynamics in some settings 111 . It has been known for some time that LKB1 has a critical role in cell polarity across a range of eukaryotes. In C. elegans 112 and Drosophila
113
, LKB1 orthologues establish cellular polarity during critical asymmetric cell divisions, and in mammalian cell culture activation of LKB1 was sufficient to promote polarization of certain epithelial cell lines 114 . Initially, it was assumed that the AMPK-related MARKs, which are homologues of C. elegans par-1 and have well-established roles in polarity, were the principal targets of LKB1 in polarity 115 . However, recent studies also support a role for AMPK in cell polarity.
In Drosophila, loss of AMPK results in altered polarity 116, 117 and in mammalian MDCK cells AMPK was activated and needed for proper repolarization and tight junction formation following a calcium switch 118, 119 . Moreover, LKB1 was shown to localize to adherens junctions in MDCK cells, and E-cadherin RNA intereference (RNAi) led to specific loss of this localization and AMPK activation at these sites 28 . The adherens junctions protein Afadin 120 and a Golgi-specific nucleotide-exchange factor for Arf5, GBF1 (Golgi-specific brefeldin A resistance factor 1) 121 , have been reported to be regulated by AMPK and may be involved in this polarity 120 , although more studies are needed to define these events and their functional consequences. In Drosophila, AMPK deficiency altered multiple polarity markers, including loss of myosin light chain (MLC) phosphorylation 116 .
Although it was suggested in this paper that MLC may be a direct substrate of AMPK, this seems unlikely as the sites do not conform to the optimal AMPK substrate motif. However, AMPK and its related family members have been reported to modulate the activity of kinases and phosphatases that regulate MLC (MLCK, MYPT1), so MLC phosphorylation may be indirectly controlled through one of these potential mechanisms.
Another recent study discovered that the microtubule plus-end protein CLIP-170 (also known as CLIP1) is a direct AMPK substrate 122 . Mutation of the AMPK site in CLIP-170 caused slower microtubule assembly, suggesting a role for AMPK in the dynamics of CLIP-170 dissociation from the growing end of microtubules. It is noteworthy that mTORC1 was also previously suggested as a kinase for CLIP-170 (ref. 123) , introducing the possibility that like ULK1, CLIP-170 may be a convergence point in the cell for AMPK and mTOR signalling. Consistent with this, besides effects on cell growth, LKB1/AMPK control of mTOR was recently reported to control cilia 124 and neuronal polarization under conditions of energy stress 125 . In addition, the regulation of CLIP-170 by AMPK is reminiscent of the regulation of MAPs (microtubule-associated proteins) by the AMPKrelated MARK kinases, which are critical in Tau hyperphosphorylation in Alzheimer's models 126, 127 . Indeed, AMPK itself has been shown to target the same sites in Tau under some conditions as well 128 . Finally, an independent study suggested a role for AMPK in polarizing neurons through control of phosphatidylinositol 3-kinase (PI3K) localization 129 . Here, AMPK was shown to directly phosphorylate kinesin light chain 2 (KLC2) and inhibit axonal growth through prevention of PI3K localization to the axonal tip. Interestingly, a previous study examined the related protein kinesin light chain 1 (KLC1) as a target of AMPK and determined it was not a real substrate in vivo 130 . Further experiments are needed to clarify whether AMPK is a bona fide kinase for KLC1 or KLC2 in vivo and in which tissues.
Emerging themes and future directions
An explosion of studies in the past 5 years has begun decoding substrates of AMPK that have roles in a variety of growth, metabolism, autophagy and cell-polarity processes. An emergent theme in the field is that AMPK and its related family members often redundantly phosphorylate a common set of substrates on the same residues, although the tissue expression and condition under which AMPK or its related family members are active vary. For example, CRTCs, Class IIa HDACs, p300, SREBP1, IRS1 and tau are reported to be regulated by AMPK and/ or its SIK-and MARK-family members depending on the cell type or conditions. As an example of the complexity to be expected, SIK1 itself is transcriptionally regulated and its kinase activity is modulated by Akt and PKA so the conditions under which it is expressed and active will be a narrow range in specific cell types only, and usually distinct from conditions where AMPK is active. Delineating the tissues and conditions in which the twelve AMPK-related kinases are active remains a critical goal for dissecting the growth and metabolic roles of their shared downstream substrates. A much more comprehensive analysis of AMPK and its family members using genetic loss-of-function approaches and RNAi is needed to decode the relative importance of each AMPK-family kinase on a given substrate for each cell type. Now with a more complete list of AMPK substrates, it is also becoming clear that there is a convergence of AMPK signalling with PI3K and Erk signalling in growth control pathways, and with insulin-and cAMP-dependent pathways in metabolic control. The convergence of these pathways reinforces the concept that there is a small core of ratelimiting regulators that control distinct aspects of biology and act as master coordinators of cell growth, metabolism and ultimately cell fate. As more targets of AMPK are decoded, the challenge will be in defining more precisely which targets are essential and relevant for the beneficial effects of AMPK activation seen in pathological states ranging from diabetes to cancer to neurological disorders. The identification of these downstream effectors will provide new targets for therapeutically treating these diseases by unlocking this endogenous mechanism that evolution has developed to restore cellular and organismal homeostasis.
